In vitro induction of fetal hemoglobin in human erythroid progenitor cells

Experimental Hematology

Volumn 31, Issue 7, 2003, Pages 586-591

  Ho, Janie A ^a   Pickens, Chrisley V ^a   Gamscik, Michael P ^b   Colvin, O Michael ^b   Ware, Russell E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; 5 AMINO 4 METHYLISOQUINOLINE 1 CARBOXALDEHYDE THIOSEMICARBAZONE; ALKYLATING AGENT; CARMUSTINE; CYTARABINE; CYTOTOXIC AGENT; ENZYME INHIBITOR; GEMCITABINE; GUANAZOLE; HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA; METHYLCELLULOSE; RIBONUCLEOTIDE REDUCTASE;

ARTICLE; BURST FORMING UNIT; CELL COUNT; CHILD; CONTROLLED STUDY; ERYTHROID PRECURSOR CELL; EXTRACTION; HEMOGLOBIN DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN INDUCTION; SICKLE CELL ANEMIA;

EID: 0038045578     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00086-9     Document Type: Article

References (41)

1. Platt O.S., Thorington B.D., Brambilla D.J., et al. Pain in sickle cell disease. N Engl J Med. 325:1991;11-16.
2. s-gene-cluster haplotypes in sickle cell anemia. Hematol Oncol Clin North Am. 5:1991;475-493.
3. Seward D., Ware R.E., Kinney R.E. Hemoglobin S-Lepore: report of two siblings and review of the literature. Am J Hematol. 44:1993;192-195.
4. Steinberg M.H., Hsu H., Nagel R.L., et al. Gender and haplotype effects upon hematological manifestations of adult sickle cell anemia. Am J Hematol. 48:1995;175.
5. Platt O.S., Brambilla D.J., Rosse W.F., et al. Mortality in sickle cell disease. N Engl J Med. 330:1994;1639-1644.
6. Steinberg M.H., Rosenstock W., Coleman M.B., et al. The effects of alpha thalassemia and microcytosis on the hematologic and vaso-occlusive severity of sickle cell anemia. Blood. 63:1984;1353-1360.
7. Baum K.F., Dunn D.T., Maude G.H., et al. The painful crisis of homozygous sickle cell disease: a study of risk factors. Arch Intern Med. 147:1987;1231-1234.
8. s-gene-cluster haplotypes as prognostic indicators of vital organ failure. Semin Hematol. 28:1991;202.
9. Phillips G., Coffey B., Tran-son-tay R., et al. Relationship of clinical severity to packed cell rheology in sickle cell anemia. Blood. 78:1991;2735-2739.
10. Embury S.H., Steinberg M.H. Genetic modulators of disease. Embury S.H., Hebbel R.P., Mohandas N., Steinberg M.H. Sickle Cell Disease: Basic Principles and Clinical Practice. 1994;279-298 Raven Press, Ltd, New York.
11. Charache S. Fetal hemoglobin, sickling, and sickle cell disease. Adv Pediatr. 37:1990;1-31.
12. Odenheimer D.J., Sarnaik S.A., Whitten C.F., et al. The relationship between fetal hemoglobin and disease severity in children with sickle cell anemia. Am J Med Genet. 27:1987;525-535.
13. Leikin S.L., Gallagher D., Kinney T.R., et al. Mortality in children and adolescents with sickle cell disease. Pediatrics. 84:1989;500-508.
14. Goldberg M.A., Brugnara C., Dover G.J., et al. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med. 323:1990;366-372.
15. Charache S., Dover G.J., Moore R.D., et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 79:1992;2555-2565.
16. Perrine S.P., Ginder G.D., Faller D.V., et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med. 328:1993;81-86.
17. Dover G.J., Brusilow S., Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood. 84:1994;339-343.
18. Charache S., Terrin M.L., Moore R.D., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 332:1995;1317-1322.
19. Kinney T.R., Helms R.W., O'Branski E.E., et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Blood. 94:1999;1550-1554.
20. Krakoff I.H., Brown N.C., Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res. 28:1968;1559-1565.
21. Papayannopoulou T., Torrealba de Ron A., Veith R., et al. Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics. Science. 224:1984;617-619.
22. Stamatoyannopoulos G., Veith R., Galanello R., Papayannopoulou T. HbF production in stressed erythropoiesis. Ann NY Acad Sci. 445:1985;188-197.
23. Yang Y.M., Pace B., Kitchens D., et al. BFU-E colony growth in response to hydroxyurea: correlation between in vitro and in vivo fetal hemoglobin induction. Am J Hematol. 56:1997;252-258.
24. Dover G.J., Humphries R.K., Moore J.G., et al. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood. 67:1986;735-738.
25. Rodgers G.P., Dover G.J., Uyesaka, et al. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med. 328:1993;73-80.
26. Wojda U., Noel P., Miller J.L. Fetal and adult hemoglobin production during adult erythropoiesis: coordinate expression correlates with cell proliferation. Blood. 99:2002;3005-3013.
27. Iyamu W.E., Adunyah S.E., Fasold H., et al. Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (Didox and Trimidox) in combination with streptozotocin. Am J Hematol. 63:2000;176-183.
28. Nocentini G. Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Crit Rev Oncol Hematol. 22:1996;89-126.
29. Moore E.C. The effects of ferrous iron and dithioerythritol on inhibition by hydroxyurea of ribonucleotide reductase. Cancer Res. 29:1969;291-297.
30. Navarra P., Preziosi P. Hydroxyurea: new insights on an old drug. Crit Rev Oncol/Hematol. 29:1999;249-255.
31. Woolley P.V. III, Dion, Kohn K.W., et al. Binding of 1-(2 chloroethyl)-3-cyclohexyl-1-nitrosourea to L1210 cell nuclear proteins. Cancer Res. 36:1976;1470-1474.
32. McCaffrey P.G., Newsome D.A., Fibach E., et al. Induction of γ-globin by histone deacetylase inhibitors. Blood. 90:1997;2075-2083.
33. Jiang J., Jordan S.J., Barr D.P., et al. In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol Pharmacol. 52:1997;1081-1086.
34. Pacelli R., Taira J., Cook J.A., et al. Hydroxyurea reacts with heme proteins to generate nitric oxide. Lancet. 347:1996;900.
35. Lassmann G., Thelander L., Graslund A. EPR stopped-flow studies of the reaction of the tyrosol radical of protein R2 from ribonucleotide reductase with hydroxyurea. Biochem Biophys Res Commun. 188:1992;879-887.
36. Kwon N.S., Stuehr D.J., Nathan C.F. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J Exp Med. 174:1991;761-767.
37. Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol. 11:2001;66-75.
38. Mankad V.N., Baliga B.S., Phillips K., Shah A.K., Yang Y.M. Relationship of burst-forming-unit-erythroid progenitors and their DNA-synthesis stage to fetal hemoglobin levels in hydroxyurea-treated patients with sickle cell anemia. Am J Hematol. 46:1994;259-263.
39. Fibach E., Prasanna P., Rodgers G.P., Samid D. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and β-thalassemia. Blood. 82:1993;2203-2209.
40. Steinberg M.H., Lu Z.M., Barton F., et al. Fetal hemoglobin (HbF) in sickle cell anemia: determinants of response to hydroxyurea (HU). Blood. 89:1997;1078-1088.
41. Ware R.E., Eggleston B., Redding-Lallinger R., et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 99:2002;10-14.